866-997-4948(US-Canada Toll Free)

Cataract - Pipeline Review, H1 2013

Published By :

Global Markets Direct

Published Date : May 2013

Category :

Oncology

No. of Pages : 55 Pages


Global Markets Directs, \'Cataract Pipeline Review, H1 2013\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Cataract, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cataract. 

Cataract Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Cataract.
  • A review of the Cataract products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Cataract pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Cataract.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Cataract pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Cataract Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Cataract 7
Cataract Therapeutics under Development by Companies 9
Cataract Therapeutics under Investigation by Universities/Institutes 10
Mid Clinical Stage Products 11
Comparative Analysis 11
Early Clinical Stage Products 12
Comparative Analysis 12
Pre-Clinical Stage Products 13
Comparative Analysis 13
Cataract Therapeutics - Products under Development by Companies 14
Cataract Therapeutics - Products under Investigation by Universities/Institutes 15
Companies Involved in Cataract Therapeutics Development 16
R-Tech Ueno, Ltd. 16
NovaLead Pharma Pvt. Ltd. 17
Omeros Corporation 18
ESBATech AG 19
Laboratorios Sophia S.A. de C.V. 20
Laila Pharmaceuticals Pvt. Ltd. 21
Cataract - Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Drug Profiles 27
VLD-01 - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
ESBA-105 - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
dexamethasone acetate - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
MTP-131 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
RTU-007 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
GPR161 Antagonist - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
PRO-155 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
caffeic acid phenethyl ester - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
LP-01309 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Cataract Therapeutics - Drug Profile Updates 40
Cataract Therapeutics - Dormant Products 45
Cataract - Product Development Milestones 46
Featured News & Press Releases 46
Nov 29, 2011: Omeros Submits Paediatric Investigation Plan Letter Of Intent For OMS302 To European Medicines Agency 46
Oct 11, 2011: Omeros Announces First Patients Treated In Phase III Clinical Program Evaluating OMS302 46
May 19, 2011: Omeros Advances OMS302 Into Phase III Clinical Development Program 47
Mar 23, 2011: Omeros\'s Ophthalmology Product OMS302 Achieves Co-Primary Endpoints In Phase IIb Clinical Study 48
Mar 22, 2011: InSite Vision Announces Positive Phase I/II Results For ISV-303 For Reduction Of Pain And Inflammation After Cataract Surgery 48
Jan 05, 2011: InSite Vision Completes Patient Enrollment In ISV-303 Phase I/II Clinical Study For Post-Surgical Ocular Pain And Swelling 49
Aug 23, 2010: InSite Vision Initiates Phase I/II Clinical Study Of ISV-303 For Post-Surgical Ocular Pain And Swelling 50
Jul 27, 2010: Omeros Initiates Phase IIb Clinical Trial For OMS302 In Patients Undergoing Cataract Surgery 51
Jan 05, 2010: Icon Bioscience Initiates Phase II/III Pivotal Clinical Study Of Novel Ophthalmic Drug Candidate IBI-10090 52
Aug 11, 2009: Omeros Announces Positive Phase I/II Trial Results Of OMS302 For Use During Ophthalmologic Surgery 52

Appendix 54
Methodology 54
Coverage 54
Secondary Research 54
Primary Research 54
Expert Panel Validation 54
Contact Us 55
Disclaimer 55

List of Table


Number of Products Under Development for Cataract, H1 2013 7
Products under Development for Cataract - Comparative Analysis, H1 2013 8
Number of Products under Development by Companies, H1 2013 9
Number of Products under Investigation by Universities/Institutes, H1 2013 10
Comparative Analysis by Mid Clinical Stage Development, H1 2013 11
Comparative Analysis by Early Clinical Stage Development, H1 2013 12
Comparative Analysis by Pre-Clinical Stage Development, H1 2013 13
Products under Development by Companies, H1 2013 14
Products under Investigation by Universities/Institutes, H1 2013 15
R-Tech Ueno, Ltd., H1 2013 16
NovaLead Pharma Pvt. Ltd., H1 2013 17
Omeros Corporation, H1 2013 18
Laboratorios Sophia S.A. de C.V., H1 2013 20
Laila Pharmaceuticals Pvt. Ltd., H1 2013 21
Assessment by Monotherapy Products, H1 2013 22
Assessment by Stage and Route of Administration, H1 2013 24
Assessment by Stage and Molecule Type, H1 2013 26
Cataract Therapeutics - Drug Profile Updates 40
Cataract Therapeutics - Dormant Products 45

List of Chart


Number of Products under Development for Cataract, H1 2013 7
Products under Development for Cataract - Comparative Analysis, H1 2013 8
Products under Development by Companies, H1 2013 9
Products under Investigation by Universities/Institutes, H1 2013 10
Mid Clinical Stage Products, H1 2013 11
Early Clinical Stage Products, H1 2013 12
Pre-Clinical Stage Products, H1 2013 13
Assessment by Monotherapy Products, H1 2013 22
Assessment by Route of Administration, H1 2013 23
Assessment by Stage and Route of Administration, H1 2013 24
Assessment by Molecule Type, H1 2013 25
Assessment by Stage and Molecule Type, H1 2013 26

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *